Saint-Prex, Switzerland, October 27, 2026
Ferring Pharmaceuticals and biotechnology company Gameto have signed an agreement for a proposed global acquisition valued at up to $1.3825 billion, marking a significant development in the women’s reproductive healthcare and fertility treatment industry. Announced on October 27, 2026, the proposed transaction aims to combine Gameto’s innovative cell-engineering platform with Ferring’s established expertise and international presence in reproductive medicine. The agreement represents a strategic move by Ferring to strengthen its reproductive healthcare portfolio and expand its capabilities in next-generation fertility treatments. The transaction value is contingent on development, regulatory and commercial milestones, rather than representing a fully paid upfront acquisition amount. Completion remains subject to customary and other closing conditions, and both companies will continue operating independently until the transaction is finalised. The proposed acquisition highlights growing pharmaceutical industry interest in innovative technologies designed to address unmet needs in women’s health and fertility care.
Ferring Strengthens Its Global Reproductive Medicine Portfolio
The proposed acquisition is expected to bring together two companies with complementary expertise in reproductive healthcare. Ferring Pharmaceuticals, a privately owned specialty biopharmaceutical company headquartered in Saint-Prex, Switzerland, has more than 50 years of experience in helping individuals and families build families through reproductive medicine. The company operates subsidiaries in more than 50 countries and markets its medicines in over 100 countries. Its business also includes established activities in gastroenterology, urology and uro-oncology gene therapy. Through the proposed transaction, Ferring aims to integrate Gameto’s scientific innovation and reproductive-health research capabilities into its existing global platform. Gameto is a biotechnology company focused on developing cell-engineering-based solutions for women’s reproductive health, with particular attention to infertility, ovarian disease and menopause. The combination could provide opportunities to advance emerging fertility technologies and potentially expand their availability through Ferring’s international commercial infrastructure. The acquisition would strengthen Ferring’s position in the evolving women’s healthcare market, where innovative approaches to fertility treatment and reproductive health are receiving increasing attention from pharmaceutical and biotechnology companies.
Gameto’s Fertilo Technology Advances Fertility Treatment Innovation
A key part of Gameto’s reproductive-health research is its Fertilo programme, which focuses on an innovative approach to in vitro maturation (IVM). The technology is designed to support the maturation of immature eggs outside the human body using specially engineered ovarian support cells derived from induced pluripotent stem cells (iPSCs). These cells are intended to recreate aspects of the natural ovarian environment and support egg maturation in laboratory conditions. Conventional in vitro fertilisation (IVF) commonly involves hormonal stimulation to encourage the development of multiple mature eggs before retrieval. Gameto’s IVM approach seeks to simplify aspects of this process and potentially reduce the duration and burden associated with fertility treatment. By developing engineered ovarian support cells, the company aims to introduce an alternative approach to existing assisted reproductive technologies. Fertilo represents an investigational cell-engineering innovation with potential applications in fertility care, although its clinical benefits and long-term effectiveness require continued evaluation. Importantly, Gameto’s In Vitro Maturation programme remains investigational in the United States and has not been approved by the U.S. Food and Drug Administration (FDA). The proposed acquisition does not itself constitute regulatory approval or establish a new authorised indication for the technology.
Advertisement
$1.3825 Billion Agreement Marks Strategic Industry Expansion
The proposed transaction, valued at up to $1.3825 billion, reflects the strategic importance of Gameto’s reproductive-health technology and broader innovation platform. The final transaction value will depend on the achievement of specified development, regulatory and commercial milestones. Ferring’s global presence and established reproductive-medicine expertise could provide a foundation for advancing Gameto’s research programmes and supporting potential future commercial development, subject to successful clinical development and regulatory requirements. Jean-Frédéric Paulsen, Chairman of the Board of Directors and Chief Executive Officer of Ferring Pharmaceuticals, highlighted the opportunity to combine the company’s reproductive-medicine experience with Gameto’s scientific innovation to advance fertility care and reach more patients worldwide. Dr. Dina Turner, Chief Executive Officer and Co-founder of Gameto, described the agreement as an important milestone for the company’s mission to transform women’s reproductive health through cell-engineering technologies. The proposed acquisition signals a growing strategic investment in biotechnology-driven fertility innovation and women’s healthcare. As the transaction progresses through its required closing conditions, the collaboration could create new opportunities for research, development and global expansion in reproductive medicine. The companies will continue their independent operations until the acquisition is completed.
Source: Ferring Pharmaceuticals, Gameto press release
